Cocaine abuse in pregnancy (original) (raw)

Review of Clinical Pharmacology and Pharmacokinetics, International Edition

Abstract

S u m m a r y: Subject of this literature review is the impact of cocaine abuse during pregnancy and its long-term consequences on the fetus. Prenatal exposure to cocaine is associated with withdrawal symptoms in the neonate. Numerous studies have reported an increased risk of cardiac anomalies such as ventricular septal defect, auricular septal defect, heart block, cardiomegaly, hypoplastic right or left side of the heart, absent of ventricle, coarctation of aorta, peripheral pulmonic stenosis, patent ductus arteriosus, aortic dissection and aortic valve prolapse and in addition, maternal cocaine abuse is associated with thickening of the interlobular arterial wall of the fetal kidney and narrowing of the lumen and genitourinary anomalies, neurobehavioral and developmental deficits in infants exposed to cocaine in utero. In humans the most common consequences of cocaine abuse during pregnancy include premature birth, lower birth weight, respiratory distress, bowel infarctions, cerebral infarctions, reduced head circumference, intrauterine developmental retardation, delayed development of fetal nervous system, increased risk for congenital cardiac defects, defects of urogenital tract, . Send reprint requests to: Anna Deltsidou, Kifisias 51, 115 23, Athens, Greece decreased fetal urine output and bladder cycle, and increased risk of seizures.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (72)

  1. Deltsidou A., Lykeridou K., Plessas S.: Licit substance abuse during pregnancy and its effects on the fetus. Epi- theor Klin. Farmakol. Farmakokinet (International Edition) 15: 21-32 (2001)
  2. National Institute of Drug and Alcohol Abuse: National pregnancy and health survey-drug use among women delivering live births. MD NCADI Publication no. BKD192 (1992)
  3. Κοκκέβη Α., Στεφανής Κ.: Τα ναρκωτικά στην Ελλάδα: Η διαχρονική πορεία της χρήσης. Ερευνητικό Πανεπιστηµια- κό Ινστιτούτο Ψυχικής Υγιεινής, Αθήνα: 71-78, 191-197 (1994)
  4. Lee E.W., D' Alonzo G.E.: Cigarette smoking, nicotine addiction and pharmacologic treatment. Arch. Intern. Med. 153: 34-48 (1993)
  5. Youngstrom N.: Fetal alcohol syndrome carries severe deficits. APA Monitor 23(4): 32 (1992)
  6. Behnke M., Eyler F.D., Conlon M., et al.: How fetal co- caine exposure increases neonatal hospital costs. Pediat- rics 99: 204-208 (1997)
  7. Ritchie J.M., Greene N.M.: In: The pharmacological basis of therapeutics. (Goodman L.S., Gilman A., eds), Pp. 300-320, MacMillan, New York, 1980
  8. Κίτσιου -Τζέλη Σ.: Παράγοντες Τερατογένεσης και Συγγενείς Ανωµαλίες. Αθήνα: 22-28, 135-160, 1992
  9. Chao C.R.: Cardiovascular effects of cocaine pregnancy. Semin. Perinatol. 20: 107-114 (1996)
  10. Dolkart L.A., Plessinger M.A.: Effect of alpha 1 receptor blockade upon maternal and fetal cardiovascular responses to cocaine. Obstet. Gynecol. 75: 745-751 (1990)
  11. Woods J.R., Plessinger M.A.: Pregnancy increases cardiovascular toxicity to cocaine. Am. J. Obstet Gynecol. 162: 529-533 (1990)
  12. Ritchie J.M., Greene N.M.: Local anesthetics. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics.( Gilman A.G., Rall T.W., Nies A.S., et al, eds) (8 th ed),Pp. 311-331, Pergamon, New York, 1990
  13. Jones K.L.: Developmental pathogenesis of defects associated with prenatal cocaine exposure: Fetal vascular disruption. Clin. Perinatol. 18: 139-146 (1991)
  14. Argyroudis E.: Principles of hemodynamic monitoring. Epitheor. Klin. Farmakol. Farmakokinet., inter. Ed. 15: 207- 210 (2001)
  15. Wagner C., Katikaneni L., Cox T., Ryan R.: The impact of prenatal drug exposure on the neonate. Obstet. Gynecol. Clin. North Am. 25: 169-194 (1998)
  16. Schenker S., Yang Y., Johnson R.F., et al.: The transfer of cocaine and its metabolites across the term human placenta. Clin. Pharmacol. Therap. 53: 329-339 (1993)
  17. Angelilli M.L., Fischer H., Delaney-Black V., et al.: History of in utero cocaine exposure in language-delayed children. Clin. Pediatr. 33: 514-516 (1994)
  18. Bender S.L., Word C.O., DiClemente R.J., et al.: The developmental implications of prenatal and / or postnatal crack cocaine exposure in preschool children: A preliminary report. J. Developm. Behavior. Pediatr. 16: 418-424 (1995)
  19. Chasnoff I.J.: Cocaine, pregnancy, and the growing child. Curr. Probl. Pediatr. 22L: 302-322 (1992)
  20. Koren G., Nulman I., Rovet J., et al.: Long-term neuro- developmental risks in children exposed in utero to co- caine. The Toronto Adoption Study. Ann. N. Y. Acad. Sci. 846: 306-13 (1998)
  21. Chiriboga C.A.: Cocaine and the fetus: Methodological issue and neurological correlates. In: Prenatal Cocaine Exposure (Konkol R.J., Olsen G.D., eds) CRC Press, Boca Raton, 1996
  22. Buehler B.A., Conover B., Andres R.L.: Teratogenic potential of cocaine. Semin. Perinatol. 20:107-114 (1996)
  23. Schuler M.E., Nair P.:Brief report: frequency of mater- nal cocaine use during pregnancy and infant neurobehav- ioral outcome. J. Pediatr. Psychol. 24(6):511-4 (1999)
  24. Oro A.S., Dixon S.D.: Perinatal cocaine and metham- phetamine exposure: Maternal and neonatal correlates. J. Pediatr. 111:571-578 (1987)
  25. Katikaneni L.D, Sallee F.R., Ibrahim H.O., et al.: Neo- natal hair analysis for benzoylecgonine: A marker for ges- tational cocaine exposure, growth at birth, and neurode- velopment based on short-term follow-up (4 to 8 months). In: Hair Testing for Drugs of Abuse: International Research on Standards and Technology. (Cone E.J., Welch M.J., Babecki M.B.G., eds), Pp. 362, MD, National Institute of Drugs Abuse, US Department of Health and Human Ser- vices, Public Health Service, National Institutes of Health, Rockville , 1995
  26. Zuckerman B., Frank D., Hingson R., et al.: Effects of maternal marijuana and cocaine use on fetal growth. N. Engl. J. Med. 320:762-768 (1989)
  27. Swanson M.W., Streissguth A.P., Sampson P.D., Olson H.C.: Prenatal cocaine and neuromotor outcome at four months: effect of duration of exposure. J. Dev. Behav. Pediatr. 20(5):325-34 (1999)
  28. Belcher H.M., Shapiro B.K., Leppert M., et al.: Se- quential neuromotor examination in children with intrauter- ine cocaine/polydrug exposure. Dev. Med. Child Neurol. 41(4):240-6 (1999)
  29. Klein J., Karaskov T., Koren G.:Clinical applications of hair testing for drugs of abuse--the Canadian experience. Forensic. Sci. Int. 107(1-3):281-8 (2000)
  30. Chiriboga C.A., Brust J.C., Bateman D., Hauser W.A.: Dose-response effect of fetal cocaine exposure on newborn neurologic function. Pediatrics 103(1):79-85 (1999)
  31. Bateman D.A., Chiriboga C.A.: Dose-response effect of cocaine on newborn head circumference. Pediatrics 106(3):E33 (2000)
  32. Kuhn L., Kline J., Ng S., Levin B., Susser M.:Cocaine use during pregnancy and intrauterine growth retardation: new insights based on maternal hair tests. Am. J. Epide- miol. 152(2):112-9 (2000)
  33. Richardson G.A.: Prenatal cocaine exposure. A longi- tudinal study of development. Ann. N. Y. Acad. Sci. 846:144-52 (1998)
  34. Esmer M.C., Rodriguez-Soto G., Carrasco-Daza D., et al.: Cloverleaf skull and multiple congenital anomalies in a girl exposed to cocaine in utero: case report and review of the literature. Childs Nerv. Syst. 16(3):176-9 (2000)
  35. Lipshultz S.E., Frassica J.J., Orav E.J.: Cardiovascular abnormalities in infants prenatally exposed to cocaine. J. Pediatr. 118: 44-51 (1991)
  36. Little B.B., Snell L.M., Klein V.R., et al.: Cocaine abuse during pregnancy: Maternal and fetal implication. Obstet. Gynecol. 73(2):157-160 (1989)
  37. Neerhof M.G., MacGregor S.N., Retzky S.S., et al.: Cocaine abuse during pregnancy: Peripartum prevalence and perinatal Am. J. Obstet. Gynecol. 161:633- 638 (1989)
  38. Rosenstein B.J., Wheeler J.S., Heid P.L.: Congenital renal abnormalities in infants with in utero cocaine expo- sure. J. Urol. 144:110-112 (1989)
  39. Madu E.C., Shala B., Baugh D.: Crack-cocaine-asso- ciated aortic dissection in early pregnancy--a case report. Angiology 50(2):163-8 (1999)
  40. Mitra S.C., Seshan S.V., Salcedo J.R., Gil J.:Maternal cocaine abuse and fetal renal arteries: a morphometric study. Pediatr. Nephrol. 14(4):315-8 (2000)
  41. Yap T.E., Diana D., Herson V., et al.: Fetal myocardial calcification associated with maternal cocaine use. Am. J. Perinatol. 11:179-183 (1994)
  42. Chasnoff I.J.: Newborn infants with drug withdrawal symptoms. Pediatr. Rev. 9C9:273 (1988)
  43. Downing G.J., Horner S.R., Kibride H.W.: Characteris- tics of prenatal cocaine exposed infants with necrotizing enterocolitis. Am. J. Dis. Child. 145:26-27 (1991)
  44. Telsey A.M., Merritt T.A., Dixon S.D.: Cocaine exposure in a term neonate: Necrotizing enterocolitis as a com- plication. Clin. Pediatr. 27:547-550 (1988)
  45. Kilic N., Buyukunal C., Dervisoglu S., et al.: Maternal cocaine abuse resulting in necrotizing enterocolitis. An experimental study in a rat model. II. Results of perfusion studies. Pediatr. Surg. Int.16(3):176-8 (2000)
  46. Hall T.R., Zaninovic A., Lewis D., et al.: Neonatal in- testinal ischemia with bowel perforation: An in utero com- plication of maternal cocaine abuse. AJR Am. J. Roent- genol. 158:1303-1304 (1992)
  47. ThÀ T.G., Young M., Rosser S.: In utero cocaine ex- posure and neonatal intestinal perforation: A case report. J. Nation. Med. Assoc. 87:889-891 (1995)
  48. Kapur R.P., Shaw G.M., Shepard T.H.: Brain hemor- rhages in cocaine-exposed human fetuses. Teratology 44: 11-18 (1991)
  49. Rais-Bahrami K., Naqvi M.: Hydranencephaly and maternal cocaine use: A case report. Clin. Pediatr. 29:729- 730 (1990)
  50. Trounce J.Q., Fagan D., Levene M.I.: Intraventricular hemorrhage and periventricular leucomalacia: Ultrasound and autopsy correlation. Arch. Dis. Child. 61:1203-1207 (1986)
  51. Dixon S.D., Bejar R.: Echoencephalographic findings in neonates associated with maternal cocaine and metham- phetamine use: Incidence and clinical correlates. J. Pediatr. 115(5):770-778 (1989)
  52. Plessinger M.A., Woods J.R.: Cocaine in pregnancy: Recent Data on Maternal and Fetal Risks. Obstet. Gynecol. Clin. North Am. 25 (1):99-112 (1998)
  53. Gibbs J.M., Weindling A.M.: Neonatal intracranial lesions following placental abruption. Eur. J. Pediatr. 153:195-197 (1994)
  54. Datta-Bhutada S., Johnson H.L., Rosen T.S.: Intrau- terine cocaine and crack exposure: neonatal outcome. J Perinatol. 18(3):183-8 (1998)
  55. Shiono P., Klebanoff M., Nugent R., et al.: The impact of cocaine exposure and marijuana use on low birth weight and preterm birth: A multicenter study. Am. J. Obstet. Gynecol. 172:19-27 (1995)
  56. Bennett A.D.: Perinatal substance abuse and the drug- exposed neonate. Adv. Nurse Pract. 7(5):32-6 (1999) 57. Chasnoff I.J.: Cocaine and pregnancy-implications for the child (editorial). West. J. Med. 150(4):456 (1989)
  57. Silva-Araujo A., Tavares M.A.: Development of the eye after gestational exposure to cocaine: Vascular develop- ment in the retina of rats and humans. Ann. N.Y. Acad. Sci. 801:274-288 (1996)
  58. Ness R.B., Grisso J.A., Hirschinger N., et al.:Cocaine and tobacco use and the risk of spontaneous abortion. N. Engl. J. Med. 340(5):333-9 (1999)
  59. Randall C.L., Cook J.L., Thomas S.E., White N.M.:Alcohol plus cocaine prenatally is more deleterious than either drug alone. Neurotoxicol. Teratol. 21(6):673-8 (1999)
  60. Pastrakuljic A., Derewlany L.O., Koren G.:Maternal cocaine use and cigarette smoking in pregnancy in relation to amino acid transport and fetal growth. Placenta 20(7):499-512 (1999)
  61. Grufferman S., Schwartz A.G., Ruymann F.B., Maurer H.M.: Parents' use of cocaine and marijuana and increased risk of rhabdomyosarcoma in their children. Cancer Causes Control 4: 217-224 (1993)
  62. Kilbride H., Castor C., Hoffman E., Fuger K.L.:Thirty- six-month outcome of prenatal cocaine exposure for term or near-term infants: impact of early case management. J. Dev. Behav. Pediatr. 21(1):19-26 (2000)
  63. Mitra S.C.: Effect of cocaine on fetal kidney and bladder function. J. Matern. Fetal Med. 8(6):262-9 (1999)
  64. Keller R.W., Snyder-Keller A.: Prenatal cocaine exposure. Ann. N. Y. Acad. Sci. 909: 217-32 (2000).
  65. LaGasse L.L., Seifer R., Lester B.M .:Interpreting re- search on prenatal substance exposure in the context of multiple confounding factors. Clin. Perinatol. 26(1): 39-54 vi (1999 )
  66. Richardson G.A., Day N.L., McGauhey P.J.: The impact of prenatal marijuana and cocaine use on the infant and child. Clin. Obstet. Gynecol. 36(2):302-18 (1993).
  67. Habbick B.: Fetal alcohol syndrome in Saskatchewan: unchanged incidence in a 20-year period. Can. J. Public Health 87(3):204-207 (1996).
  68. Khouzam H.R.: Helping your patients beat cocaine addiction. The four dimensions of treatment. Postgrad. Med. 105(3): 185-191 (1999).
  69. Weisdorf T., Parran T.V., Graham A., Snyder C.:Comparison of pregnancy-specific interventions to a traditional treatment program for cocaine-addicted pregnant women. J. Subst. Abuse Treat. 16(1):39-45 (1999).
  70. Deltsidou A., Lykeridou K., Plessas S.: Congenital anomalies and aetiology. Epitheor Klin. Farmakol. Farma- kokinet. (International Edition) 14: 111-115 (2000).
  71. Δελτσίδου Α., Λυκερίδου Κ., Πλέσσας Σ.: Μεταφορά φαρµάκων δια µέσου του πλακούντα. Επιθ. Κλιν. Φαρµακ. Φαρµακοκ. 18: 173-180 (2000)
  72. Cayol V., Corcos M., Clervoy P., Speranza M.: Pregnancy and drug abuse: current situation and therapeutic strategies. Ann. Med. Intern. (Paris) 151 Suppl B: 20-26 (2000)